Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Viridian Therapeutics. The associated price target is $46.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors related to Viridian Therapeutics’ recent developments. The company has successfully completed enrollment in the pivotal REVEAL program with its VRDN-003, which is a significant milestone that could drive future growth. Additionally, Viridian’s pipeline updates suggest a promising outlook, further supporting the positive rating.
Another factor influencing the Buy rating is the potential market impact of Viridian’s developments, which are positioned to address unmet medical needs. The strategic advancements in their pipeline, coupled with the completion of key program enrollments, indicate a strong potential for value creation. These elements collectively contribute to the optimistic assessment of Viridian’s stock potential.
Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Eledon Pharmaceuticals, and Dianthus Therapeutics. According to TipRanks, Katkhuda has an average return of 30.4% and a 52.53% success rate on recommended stocks.
In another report released on September 16, Leerink Partners also reiterated a Buy rating on the stock with a $0.00 price target.